A meta-analysis of 9 clinical trials found no increased cancer risk with tirzepatide, but the studies were too short to be definitive.
No increased cancer riskAcross 9 randomized controlled trials lasting 36–72 weeks, tirzepatide showed no increase in any cancer type
What the researchers found
Across all 9 trials, tirzepatide did not increase the risk of cancer overall or any specific cancer type. This held true regardless of what the comparison drug was.
However, the authors stress this is preliminary. The trials were short (36 to 72 weeks), which is not long enough to detect most drug-related cancer signals. Cancer takes years to develop, and these studies were designed to measure diabetes outcomes, not cancer risk.
Why it matters
Any new widely-prescribed drug needs cancer safety data. Tirzepatide is being used by millions for diabetes and weight loss. Previous GLP-1 drugs raised early concerns about pancreatic and thyroid cancers that were largely not confirmed in longer studies. This meta-analysis provides early reassurance for tirzepatide, though longer follow-up is essential.
The numbers in context
- 9 randomized controlled trials included
- Study durations: 36 to 72 weeks
- No significant increase in risk for any cancer type or overall cancer
- Small number of total cancer events across all trials (exact count not stated)
How the study worked
The researchers conducted a meta-analysis of all available phase 2 and phase 3 randomized controlled trials evaluating tirzepatide in type 2 diabetes, published up to April 2024. They pooled data from 9 trials. The primary endpoint was risk of any cancer. Secondary endpoints covered specific cancer types. Subgroup analyses looked at different comparator drugs.
Who was studied
People with type 2 diabetes in phase 2/3 tirzepatide trials
What this study cannot tell us
The biggest limitation is time. Cancer typically develops over years, and these trials lasted only 36 to 72 weeks. The number of cancer events was small, reducing statistical power. The trials were not designed to detect cancer as a primary outcome. This is hypothesis-generating, not definitive.
How to read the evidence
Rated moderate: meta-analysis of randomized trials provides good methodology, but trial durations were too short and cancer events too few for definitive conclusions.
When this study was published
Published in 2024 analyzing trials through April 2024. Tirzepatide was only approved in 2022, so long-term data is naturally limited.
The bigger picture
Previous GLP-1 drugs raised early concerns about pancreatic and thyroid cancers that were largely not confirmed in longer studies. This meta-analysis provides early reassurance for tirzepatide, but longer follow-up is essential.
Questions still open
- Will longer-term studies reveal a cancer signal that short trials missed?
- Does the GIP component of tirzepatide have different cancer implications than GLP-1 alone?
Common questions
Does tirzepatide cause cancer?
Should I worry about cancer while taking tirzepatide?
Read the original research
Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Diabetes research and clinical practice, 213, 111758
Citation
Popovic, Djordje S; Patoulias, Dimitrios; Popovic, Lazar S; Karakasis, Paschalis; Papanas, Nikolaos; Mantzoros, Christos S. (2024). Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.. Diabetes research and clinical practice, 213, 111758. https://doi.org/10.1016/j.diabres.2024.111758